AngioDynamics' (ANGO) AlphaVac System Gets CE Mark Approval [Yahoo! Finance]
![Yahoo! Finance](../../../Content/images/providers/Yahoo! Finance.png)
AngioDynamics, Inc. (ANGO)
Last angiodynamics, inc. earnings: 4/7 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.angiodynamics.com/investor-relations
Company Research
Source: Yahoo! Finance
The application of the AlphaVac F1885 System in the non-surgical excision of thrombi or emboli from the venous vasculature is enhanced by the CE Mark approval, which is likely a significant step forward in improving patient care and safety for endovascular therapies in the EU, a market with a higher prevalence of PE compared with the United States. Price Performance In the past six months, ANGO's shares have lost 14.5% against the industry's rise of 20.5%. The S&P 500 has gained 16.7% in the same time frame. Image Source: Zacks Investment Research More on AlphaVac F1885 System At present, the AlphaVac F1885 System is authorized for utilization as an emergency first-line tool for managing PE and eliminating thromboemboli from the venous system. The components of the system include an ergonomic handle, an obturator, a waste bag assembly, and an 85-degree-angled 18F cannula. The APEX-AV study was created to provide safety and efficacy data for a clearance specific to PE. Mor
Show less
Read more
Impact Snapshot
Event Time:
ANGO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANGO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANGO alerts
High impacting AngioDynamics, Inc. news events
Weekly update
A roundup of the hottest topics
ANGO
News
- Venous Thromboembolism Treatment Market to be Worth $4.40 Billion by 2030 - Exclusive Report by Meticulous Research® [Yahoo! Finance]Yahoo! Finance
- First patient implanted with Philips' Duo Venous stent system [Yahoo! Finance]Yahoo! Finance
- Investors in AngioDynamics (NASDAQ:ANGO) have unfortunately lost 75% over the last three years [Yahoo! Finance]Yahoo! Finance
- AngioDynamics, Inc. (NASDAQ: ANGO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.MarketBeat
- AngioDynamics receives CE Mark approval in Europe for AlphaVac F1885 System [Seeking Alpha]Seeking Alpha
ANGO
Earnings
- 4/4/24 - Miss
ANGO
Sec Filings
- 5/30/24 - Form SC
- 4/9/24 - Form 10-Q
- 4/8/24 - Form 4
- ANGO's page on the SEC website